Advancing Precision Oncology Through Synthetic Lethality

Synthetic lethality and the future of cancer treatment

The SyLAR (Synthetic Lethality-based Anticancer Therapy) project is one of the most advanced initiatives funded under the PRIN 2022 programme. Coordinated by the University of Milan with key participation from the University of Bologna, the project brings together a multidisciplinary consortium spanning chemistry, molecular biology, and pharmacology. Its overarching goal is to address a fundamental challenge in oncology: how to selectively eliminate cancer cells while preserving healthy tissue.

At the core of SyLAR lies the concept of synthetic lethality, a mechanism where the simultaneous disruption of two genes results in cell death, while the disruption of either gene alone does not. The project focuses on DNA repair pathways, particularly interactions involving RAD51 and BRCA2, which are critical for tumor survival. By designing small-molecule inhibitors targeting these pathways, SyLAR aims to create highly selective anticancer therapies. It also explores combination strategies with PARP inhibitors, extending approaches already validated in clinical oncology.

Research structure and scientific objectives

The SyLAR consortium integrates expertise from multiple Italian universities and research centers. Chemical research teams focus on the synthesis of candidate compounds, while biological laboratories test their activity in cellular and preclinical models. This translational approach ensures that discoveries can move efficiently from laboratory research toward clinical application.

The main objectives include identifying novel therapeutic targets, developing innovative inhibitors, and investigating resistance mechanisms in aggressive cancers such as pancreatic tumors. The project also explores multi-target strategies, which may enhance treatment effectiveness and durability.

Impact on oncology research and innovation

The impact of SyLAR is significant at both the scientific and societal levels. Scientifically, it advances understanding of DNA repair mechanisms and their role in cancer progression. From an innovation perspective, it may lead to new drug candidates, patents, and follow-up funding under European programmes such as Horizon Europe.

More broadly, SyLAR aligns with global trends in precision medicine, where treatments are tailored to individual genetic profiles. By improving treatment selectivity and efficacy, the project has the potential to reduce side effects and improve patient outcomes, strengthening Italy’s role in biomedical innovation.

Key takeaways

• Focus on synthetic lethality for cancer therapy

• Strong interdisciplinary collaboration across Italian universities

• Development of targeted and less toxic treatments

• Potential for drug innovation and international research impact

  
  

FAQ: SyLAR PRIN Project

What is synthetic lethality? It is a strategy where targeting two genes simultaneously causes selective cancer cell death.

Why is SyLAR important? It advances precision oncology, improving treatment effectiveness while reducing side effects.

Who are the main partners? The project is coordinated by the University of Milan with partners such as the University of Bologna.